Assessing the stability of daptomycin in icodextrin-based peritoneal dialysis solution.

IF 2.7 3区医学 Q2 UROLOGY & NEPHROLOGY

Peritoneal Dialysis International Pub Date : 2024-10-15 DOI:10.1177/08968608241283526

Hiroyuki Suzuki, Kasumi Kudo, Takashi Uno, Taisuke Konno, Kouji Okada, Yasuyuki Agatsuma, Hitoshi Nakamura, Yuriko Murai

{"title":"Assessing the stability of daptomycin in icodextrin-based peritoneal dialysis solution.","authors":"Hiroyuki Suzuki, Kasumi Kudo, Takashi Uno, Taisuke Konno, Kouji Okada, Yasuyuki Agatsuma, Hitoshi Nakamura, Yuriko Murai","doi":"10.1177/08968608241283526","DOIUrl":null,"url":null,"abstract":"Background: The stability of antimicrobials in peritonitis during peritoneal dialysis (PD) solutions is a critical factor influencing treatment success. This study investigated the stability of daptomycin (DAP) when combined with icodextrin-based PD solution, by measuring DAP concentrations and observing any structural changes.Methods: A dose of DAP (350 mg) was dissolved in 7 mL of saline in a clean bench. The solution was then injected into the large compartment (1,260 mL) of NICOPELIQ® Peritoneal Dialysis Solution and thoroughly mixed. Samples were collected at intervals ranging from 0 to 336 h (7 points in total). The concentration of DAP was quantified using high-performance liquid chromatography (HPLC). The structure of any unidentified peaks was determined using HPLC coupled with electrospray ionization tandem mass spectrometry.Results: DAP maintained 90% of the initial concentration in NICOPELIC® for 72 h at room temperature and 12 h at 37 °C. Unidentified peaks, distinct from DAP, were detected during analysis. Further investigation indicated that these peaks corresponded to anhydrated DAP.Conclusions: The findings from this stability study are expected to enhance the effectiveness of outpatient management and preparation for treating peritonitis using DAP.","PeriodicalId":19969,"journal":{"name":"Peritoneal Dialysis International","volume":null,"pages":null},"PeriodicalIF":2.7000,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Peritoneal Dialysis International","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/08968608241283526","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The stability of antimicrobials in peritonitis during peritoneal dialysis (PD) solutions is a critical factor influencing treatment success. This study investigated the stability of daptomycin (DAP) when combined with icodextrin-based PD solution, by measuring DAP concentrations and observing any structural changes.

Methods: A dose of DAP (350 mg) was dissolved in 7 mL of saline in a clean bench. The solution was then injected into the large compartment (1,260 mL) of NICOPELIQ^® Peritoneal Dialysis Solution and thoroughly mixed. Samples were collected at intervals ranging from 0 to 336 h (7 points in total). The concentration of DAP was quantified using high-performance liquid chromatography (HPLC). The structure of any unidentified peaks was determined using HPLC coupled with electrospray ionization tandem mass spectrometry.

Results: DAP maintained 90% of the initial concentration in NICOPELIC^® for 72 h at room temperature and 12 h at 37 °C. Unidentified peaks, distinct from DAP, were detected during analysis. Further investigation indicated that these peaks corresponded to anhydrated DAP.

Conclusions: The findings from this stability study are expected to enhance the effectiveness of outpatient management and preparation for treating peritonitis using DAP.

查看原文本刊更多论文

评估腹膜透析液中基于糊精的达托霉素的稳定性。

背景：腹膜透析（PD）溶液中抗菌药物在腹膜炎中的稳定性是影响治疗成功与否的关键因素。本研究通过测量达托霉素（DAP）的浓度并观察其结构变化，研究了达托霉素（DAP）与基于糊精的腹膜透析液结合后的稳定性：方法：在干净的工作台上，将一定剂量的 DAP（350 毫克）溶解在 7 毫升生理盐水中。然后将该溶液注入 NICOPELIQ® 腹膜透析液的大格（1,260 mL）中并充分混合。每隔 0 至 336 小时采集一次样本（共 7 个点）。使用高效液相色谱法（HPLC）对 DAP 的浓度进行定量。使用高效液相色谱法和电喷雾离子化串联质谱法确定未识别峰的结构：结果：在室温条件下 72 小时和 37 °C 条件下 12 小时内，DAP 在 NICOPELIC® 中保持了初始浓度的 90%。分析过程中检测到了不同于 DAP 的不明峰。进一步研究表明，这些峰值与无水 DAP 相对应：这项稳定性研究的结果有望提高门诊管理的有效性，并为使用 DAP 治疗腹膜炎做好准备。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Peritoneal Dialysis International 医学-泌尿学与肾脏学

CiteScore

6.00

自引率

17.90%

发文量

审稿时长

6-12 weeks

期刊介绍： Peritoneal Dialysis International (PDI) is an international publication dedicated to peritoneal dialysis. PDI welcomes original contributions dealing with all aspects of peritoneal dialysis from scientists working in the peritoneal dialysis field around the world. Peritoneal Dialysis International is included in Index Medicus and indexed in Current Contents/Clinical Practice, the Science Citation Index, and Excerpta Medica (Nephrology/Urology Core Journal). It is also abstracted and indexed in Chemical Abstracts (CA), as well as being indexed in Embase as a priority journal.